The article highlights that Jazz Pharmaceuticals is experiencing solid earnings estimate revisions. Such revisions are often a positive indicator for future stock performance, suggesting that the market expects better-than-anticipated financial results. This can lead to increased investor interest and buying pressure, potentially driving the stock price higher in the short term.